Dexcom, Inc.
Thesis
Dexcom is overvalued due to market misconceptions about the competitive dynamics in the continuous glucose monitoring (CGM) industry and the actual patient benefits of its products. The company faces increasing competition and pricing pressure, leading to an aggressive valuation that does not reflect the true market potential.
Did it work?
The pitch is a short thesis based on competitive pressure and valuation compression in CGM, but no price performance or elapsed time is provided, and no specific catalysts (e.g., share loss to competitors, pricing collapse, guidance cuts) are cited that could be checked against known events. Without either price data or confirmation that the competitive/pricing dynamics materially damaged Dexcom's valuation, there is no basis to judge the thesis. The verdict remains open.